NASDAQ:SNTI Senti Biosciences (SNTI) Stock Price, News & Analysis $2.15 +0.04 (+1.90%) (As of 10/11/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About Senti Biosciences Stock (NASDAQ:SNTI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Key Stats Today's Range$2.08▼$2.2150-Day Range$1.58▼$3.1552-Week Range$1.52▼$8.48Volume20,900 shsAverage Volume252,406 shsMarket Capitalization$98.37 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewSenti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Read More… Elon puts it all on the line… to save America (Ad)Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. Watch this new documentary and you’ll discover what Elon knows, Senti Biosciences Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks30th Percentile Overall ScoreSNTI MarketRank™: Senti Biosciences scored higher than 30% of companies evaluated by MarketBeat, and ranked 858th out of 997 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Senti Biosciences.Read more about Senti Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Senti Biosciences is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Senti Biosciences is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSenti Biosciences has a P/B Ratio of 0.14. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Senti Biosciences' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.42% of the float of Senti Biosciences has been sold short.Short Interest Ratio / Days to CoverSenti Biosciences has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Senti Biosciences has recently decreased by 0.72%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSenti Biosciences does not currently pay a dividend.Dividend GrowthSenti Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.42% of the float of Senti Biosciences has been sold short.Short Interest Ratio / Days to CoverSenti Biosciences has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Senti Biosciences has recently decreased by 0.72%, indicating that investor sentiment is improving. News and Social Media4.0 / 5News Sentiment1.25 News SentimentSenti Biosciences has a news sentiment score of 1.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Senti Biosciences this week, compared to 0 articles on an average week.Search Interest2 people have searched for SNTI on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows2 people have added Senti Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Senti Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders15.90% of the stock of Senti Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 25.73% of the stock of Senti Biosciences is held by institutions.Read more about Senti Biosciences' insider trading history. SNTI Stock News HeadlinesSenti Biosciences (NASDAQ:SNTI) Stock Quotes, Forecast and News SummarySeptember 26, 2024 | benzinga.comSenti Bio to Participate in Upcoming Investor ConferencesSeptember 3, 2024 | globenewswire.comElon puts it all on the line… to save AmericaElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. October 12, 2024 | Porter & Company (Ad)Senti Biosciences, Inc.: Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline HighlightsAugust 14, 2024 | finanznachrichten.deSNTI Stock Earnings: Senti Biosciences Reported Results for Q2 2024August 14, 2024 | investorplace.comSenti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline HighlightsAugust 13, 2024 | globenewswire.comSenti Bio Announces Execution of Grant Award from California Institute for Regenerative Medicines (CIRM) for Clinical Development of SENTI-202August 5, 2024 | globenewswire.comTech icon leads $125 million push to develop cancer immunotherapiesJuly 20, 2024 | bizjournals.comSee More Headlines SNTI Stock Analysis - Frequently Asked Questions How have SNTI shares performed this year? Senti Biosciences' stock was trading at $6.60 at the beginning of 2024. Since then, SNTI shares have decreased by 67.4% and is now trading at $2.15. View the best growth stocks for 2024 here. How were Senti Biosciences' earnings last quarter? Senti Biosciences, Inc. (NASDAQ:SNTI) issued its quarterly earnings results on Tuesday, August, 13th. The company reported ($2.45) EPS for the quarter. When did Senti Biosciences' stock split? Senti Biosciences shares reverse split on the morning of Thursday, July 18th 2024. The 1-10 reverse split was announced on Thursday, July 18th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 18th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Senti Biosciences? Shares of SNTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Senti Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Senti Biosciences investors own include NVIDIA (NVDA), PayPal (PYPL), Meta Platforms (META), Pfizer (PFE), Advanced Micro Devices (AMD), Coinbase Global (COIN) and SoFi Technologies (SOFI). Company Calendar Last Earnings8/13/2024Today10/11/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SNTI CUSIPN/A CIK1854270 Webwww.sentibio.com Phone650-239-2030FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-71,060,000.00 Net MarginsN/A Pretax Margin-23,259.76% Return on Equity-84.70% Return on Assets-48.10% Debt Debt-to-Equity RatioN/A Current Ratio4.89 Quick Ratio4.89 Sales & Book Value Annual Sales$255,000.00 Price / Sales385.78 Cash FlowN/A Price / Cash FlowN/A Book Value$15.02 per share Price / Book0.14Miscellaneous Outstanding Shares45,755,000Free Float3,851,000Market Cap$98.37 million OptionableNot Optionable Beta2.75 This page (NASDAQ:SNTI) was last updated on 10/12/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored[SHOCKING] Crypto Document Leak…A shocking leak has revealed Japanese electronics giant Sony is now starting its own blockchain. This move ...Crypto 101 Media | SponsoredThe Crypto Whisperer Just Sounded the AlarmThe 2024 Altcoin Eruption is Almost Here (Get in by Nov. 4) In late 2020, Ian King urged his readers to tak...Banyan Hill Publishing | SponsoredDon’t Miss Out: Elon’s Game-Changing InventionWhen you click here you'll discover what Elon Musk's newest invention can do… And how it works… You migh...InvestorPlace | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Senti Biosciences, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Senti Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.